Stratus Therapeutics
Stratus Therapeutics is a biotechnology company developing on-demand, off-the-shelf hematopoietic stem and progenitor cell therapies. The company’s platform uses mechanotransduction-mediated activation of a mechanosensitive ion channel to generate transgene-free, long-term repopulating hematopoietic stem cells from human pluripotent/hemogenic endothelial sources. Lead clinical candidate is an allogeneic HSC/HPC graft intended for indications where hematopoietic stem cell transplantation is standard of care. The company conducts preclinical IND-enabling studies, maintains master cell banks to provide HLA-matched coverage strategies, and operates R&D and GMP manufacturing capabilities in Massachusetts.
Industries
Nr. of Employees
small (1-50)
Stratus Therapeutics
Headquarters: 215 First St., Suites 340-350, Cambridge, MA 02142
Products
On‑demand allogeneic hematopoietic stem and progenitor cell therapy (lead clinical candidate)
An off-the-shelf allogeneic graft composed of hematopoietic stem cells and progenitor cells engineered for high stem cell content and minimal T cells, intended to enable durable multilineage engraftment and near-term immune reconstitution for indications where HSCT is standard of care.
On‑demand allogeneic hematopoietic stem and progenitor cell therapy (lead clinical candidate)
An off-the-shelf allogeneic graft composed of hematopoietic stem cells and progenitor cells engineered for high stem cell content and minimal T cells, intended to enable durable multilineage engraftment and near-term immune reconstitution for indications where HSCT is standard of care.
Expertise Areas
- Hematopoietic stem cell and progenitor cell therapy development
- Preclinical modeling and in vivo engraftment studies
- Cell therapy manufacturing and bioprocess scale-up
- Quality systems and regulatory compliance for ATMPs
Key Technologies
- Mechanotransduction-mediated HSC generation (PIEZO1 activation)
- Human pluripotent stem cell differentiation to HSCs (hPSC/iPSC)
- Pharmacological mimicry of mechanical cues
- HLA-matched master cell banking
News & Updates
Appointment of Dr. Ardem Patapoutian to the company’s scientific advisory board; highlights role of mechanosensitive ion channel research in platform development.
Publication detailing PIEZO1 activation-mediated generation of transgene-free long-term hematopoietic stem cells; foundational data for the company’s platform.
Appointment of an experienced R&D leader to accelerate development of the hematopoietic stem cell platform.
Company announced renaming and repositioning to emphasize development of an on-demand HSC/HPC platform.
Announcement of approximately $50M Series A-1 financing to support clinical advancement, in-house manufacturing, and growth.
Board-appointed CEO with prior biopharma operational and investment banking experience.
Appointment of Dr. Ardem Patapoutian to the company’s scientific advisory board; highlights role of mechanosensitive ion channel research in platform development.
Publication detailing PIEZO1 activation-mediated generation of transgene-free long-term hematopoietic stem cells; foundational data for the company’s platform.
Appointment of an experienced R&D leader to accelerate development of the hematopoietic stem cell platform.
Company announced renaming and repositioning to emphasize development of an on-demand HSC/HPC platform.
Announcement of approximately $50M Series A-1 financing to support clinical advancement, in-house manufacturing, and growth.
Board-appointed CEO with prior biopharma operational and investment banking experience.